Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenylbutyrate Continuous Infusion in Pediatric CNS Malignancy
NCT00006450Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2000
- Countries
- 1
- Sponsor
- National Cancer Institute
- Modality
- Small Molecules
- Conditions
- brain tumor
01
Overview
Phase 2, open-label, single-arm trial of sodium phenylbutyrate in brain tumor, sponsored by National Cancer Institute. Primary endpoint: Tumor Response to Treatment. Started Nov 2000; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Phenylbutyrate
Continuous infusion of Phenylbutyrate
03
Who it enrols
Patients 2-21 years old with recurrent or progressive brain tumors after prior therapy, adequate organ function, and no significant systemic illness.
04
Endpoints
Primary
Tumor Response to Treatment
Secondary
Incidence of Adverse Events
Beyond the preview
Go deeper on NCT00006450.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006450.